Medios AG has appointed Stefan Bauerreis as a member of the Executive Board and as the Company's new Chief Financial Officer, effective April 15, 2026. He succeeds Falk Neukirch, who will step down at his own request at the end of his regular term of office on April 30, 2026.
This leadership change is significant for Medios AG as the company positions itself for future growth in the competitive specialty pharmaceutical market. Bauerreis brings extensive financial expertise from his previous roles as Chief Financial Officer of the Stabilus Group and various senior finance positions within the Schaeffler Group spanning more than two decades. His experience includes serving as CFO for the Europe region and CFO for Germany, providing him with deep knowledge of corporate accounting, controlling, financing, and international company transformation.
Dr. Yann Samson, Chairman of the Supervisory Board of Medios AG, emphasized the strategic importance of this appointment, stating that Bauerreis combines operational excellence with strategic foresight and has demonstrated the ability to successfully lead companies through periods of transformation. The company believes his expertise will provide important momentum for Medios's future development.
Bauerreis expressed enthusiasm for his new role, stating he looks forward to helping shape the future of Medios AG as part of the Executive Board. As CFO, he aims to contribute to expanding the success of the Medios Group and strengthening its position as a leading Specialty Pharma company both nationally and internationally, serving the best interests of shareholders and employees.
The timing of this leadership transition coincides with several important events for the Medios Group in the 2026 financial year, including the Metzler Small Cap Days in Frankfurt on April 15, the TP ICAP Midcap Conference in Paris on May 6, and the company's Annual General Meeting on June 10. These events will provide opportunities for the new CFO to engage with investors and stakeholders as Medios continues its growth trajectory.
Medios AG operates as Germany's first listed specialty pharmaceutical company, with shares listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) and included in the SDAX selection index. The company focuses on pioneering individualized medicine to make innovative therapies available through partnerships with pharmacies, specialist practices, and pharmaceutical companies. More information about the company's approach to individualized medicine can be found at https://app.medios.group/en/individualizedmedicine.
The appointment of an experienced financial leader like Bauerreis signals Medios AG's commitment to strengthening its financial management as it navigates the evolving pharmaceutical landscape. His background in publicly traded companies, including SDAX and MDAX companies, positions him well to support Medios's strategic objectives and financial performance in the coming years.
